Focus: Capital Seeking New Directions, Second-Half 2024 A-Share Investment Landscape Emerges

On August 12, the innovative drug concept strengthened again, with Baihua Pharmaceutical quickly hitting the daily limit in early trading, achieving a seven-consecutive-day rally. The stock is currently trading at 14.03 yuan per share, with a turnover exceeding 900 million yuan, and a total market capitalization of 5.4 billion yuan.

Previously, on August 10, Baihua Pharmaceutical issued an announcement regarding abnormal stock trading fluctuations. It stated that the company achieved an operating revenue of 67.1829 million yuan in the first quarter of 2026, a year-on-year decrease of 30.68%, and a net profit attributable to the parent company of 6.6427 million yuan, a year-on-year decrease of 67.94%. The company's fundamentals have not undergone significant changes, and no major adjustments have been made to the market environment or industry policies. The stock price has diverged from the company's fundamentals. As of now, the company's latest rolling P/E ratio is 167.49 times, compared to the industry's recent P/E ratio of approximately 33.67 times, indicating that the company's relevant metrics are significantly above the overall industry valuation level. The company's stock price has experienced considerable short-term volatility, and the stock has accumulated significant secondary market trading risks, with a risk of a rapid decline in the future.

In the innovative drug sector, Yuzhen Pharmaceutical rose over 9%, Wanbang Pharmaceutical gained over 8%, and Hongbo Pharmaceutical, Kunming Pharmaceutical, Longshen Pharma, and Medicilon also followed with gains.